From Almost Universally Fatal to Largely Treatable iTTP – American Society of Hematology
American Society of Hematology shared a post on LinkedIn about a recent article by Ahmet Emre Eşkazan, published in The Hematologist, adding:
“Immune-mediated thrombocytopenic purpura (iTTP) has undergone one of the most remarkable transformations in modern hematology.
Once considered almost universally fatal, it is now a largely treatable disease due to advances in therapeutic plasma exchange (TPE), immunosuppression, and targeted therapy.
Nevertheless, important challenges remain in early diagnosis, equitable access to treatment, relapse prevention, and long-term patient outcomes.”
Title: Small Vessels, Big Consequences: Immune-Mediated Thrombotic Thrombocytopenic Purpura
Authors: Ahmet Emre Eşkazan
Other posts featuring ASH on Hemostasis Today.
-
Aug 27, 2026, 00:14Join EHA ReCon 2027 in Malta – Explore RNA Biology to Therapeutics
-
Aug 27, 2026, 00:04John Cush: Registry Study Confirms Real-World Liver Risks with Avacopan
-
Aug 26, 2026, 23:57N. Mariana S. Vasquez: TTP vs ITP vs DIC
-
Aug 26, 2026, 23:49Mauricio Ambriz: Pathogenesis of Autoimmune Hemolytic Anemia Mediated by Warm and Cold Antibodies
-
Aug 26, 2026, 23:45Can Thromboinflammation Biomarkers Improve PE Mortality Prediction? – RPTH Journal
-
Aug 26, 2026, 23:39Eric Topol: Shingles Vaccine Associated with 10% Drop in Heart Failure and Stroke
-
Aug 26, 2026, 22:59Debbe McCall: Should Frail Elderly Patients Stable on Warfarin Switch to DOACs?
-
Aug 26, 2026, 18:38Maia Meier: Muhiba’s Story of Courage, Resilience and Hope With Type 3 VWD
-
Aug 26, 2026, 18:27Isabella Presch: Not Every Genome-Editing Program Needs to Start From Zero